First name: Alastair
Institution: Newcastle University and Newcastle upon Tyne NHS Foundation Trust
Professor Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 4 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with lung cancer. He is a member of Lung CSG, leads systemic therapy research for NSCLC in the North-East, with a portfolio of Phase I-IV studies and is the sub-specialty lead for lung cancer for the North-East England and North Cumbria NIHR CRN. In addition he is the Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub, the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in lung cancer), and leads the Pharmacodynamic Biomarker team at Newcastle University Cancer.
- Lung Cancer
- Early Drug development
- Personalised Medicine
- Circulating Biomarkers
- Treatment of cancer in the elderly